Insiders · VNDA

Phaedra Chrousos

Director at Vanda Pharmaceuticals Inc. (VNDA)

Phaedra Chrousos has filed 7 insider reports with the SEC since June 2021, as director at Vanda Pharmaceuticals Inc. (VNDA). Phaedra Chrousos made no open-market purchases or sales in the last 12 months. The latest filing, on June 8, 2026, reports grant or award at Vanda Pharmaceuticals Inc. (VNDA).

Filings
7
Companies
1
Bought on market
None
Sold on market
$40.1K

Companies where Phaedra Chrousos is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Vanda Pharmaceuticals Inc. logo
VNDA
Vanda Pharmaceuticals Inc.
Director164,950$40.1K$3.75Jun 8, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Phaedra Chrousos with

Other insiders at the same companies

Questions about Phaedra Chrousos

What is Phaedra Chrousos's role at Vanda Pharmaceuticals Inc.?
Phaedra Chrousos reports to the SEC as director at Vanda Pharmaceuticals Inc. (VNDA), according to the latest filing on June 8, 2026.
How many shares does Phaedra Chrousos own?
After the latest filing that states it, Phaedra Chrousos directly owned 164,950 shares of Vanda Pharmaceuticals Inc. (VNDA). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Phaedra Chrousos bought or sold stock recently?
The most recent open-market sale was on June 14, 2021: sold 2,075 shares of Vanda Pharmaceuticals Inc. (VNDA) for $40.1K at an average of $19.34.
How do I get alerts when Phaedra Chrousos files?
Follow Phaedra Chrousos on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Phaedra Chrousos (SEC CIK 0001774518). Totals count each trade once, skipping amendments whose original is on file, from Jun 14, 2021 on. View on SEC EDGAR